Department of Surgery and Comprehensive Transplant Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Hum Immunol. 2010 Jun;71(6):566-76. doi: 10.1016/j.humimm.2010.02.008. Epub 2010 Mar 11.
Ex vivo identification of donor-specific unresponsiveness in organ transplant recipients is important for immunosuppression (IS) minimization. We tested three groups of stable living, related-donor kidney transplant patients up to 11 years postoperatively, i.e., 20 haploidenticals with donor bone marrow cell (DBMC) infusions, eight noninfused haploidentical controls (haplo controls), and 11 HLA-identical controls (HLA-id), using multiple ex vivo immune assays. We observed that no patients developed donor-specific antibodies. The majority showed donor-specific CTL unresponsiveness from year 1 onward. Thirteen of 20 DBMC recipients became specifically donor MLR nonreactive. Depletion of donor cells in DBMC recipients still MLR reactive increased donor-specific reactivity by 75% +/- 36% (p = 0.04). Adding them back in low concentration caused antigen specific inhibition. The frequencies of ELISPOT granzyme-B and interferon-gamma-producing cells somewhat paralleled the CTL and MLR responses. In the trans vivo DTH, 14 of 19 DBMC recipients demonstrated donor-specific unresponsiveness and 16 of 19 showed "linked suppression," vs none of eight and one of eight haplo controls and vs six of 10 and one of 10 HLA-ids, respectively. Most importantly, when all six assays were performed simultaneously, 10 of 18 DBMC, five of 10 HLA-ids, and no haplo controls were specifically donor unresponsive long term. We propose that a cluster analysis combining these assays will reveal tolerant recipients in whom IS minimization may safely be tested. This appears to have occurred in many DBMC-infused recipients.
在器官移植受者中体外鉴定供者特异性无反应性对于免疫抑制(IS)的最小化很重要。我们测试了三组稳定的活体相关供体肾移植患者,即 20 例接受供体骨髓细胞(DBMC)输注的单倍体、8 例未输注的单倍体对照(单倍体对照)和 11 例 HLA 相同对照(HLA-id),使用多种体外免疫检测。我们观察到没有患者产生供者特异性抗体。大多数患者从第 1 年开始表现出供者特异性 CTL 无反应性。20 例 DBMC 受者中有 13 例成为特异性供者 MLR 无反应性。在 DBMC 受者中耗尽供体细胞仍能使 MLR 反应性增加 75% +/- 36%(p = 0.04)。以低浓度添加回供体细胞会导致抗原特异性抑制。ELISPOT 颗粒酶 B 和干扰素-γ产生细胞的频率与 CTL 和 MLR 反应有些相似。在体内 DTH 中,19 例 DBMC 受者中的 14 例表现出供者特异性无反应性,19 例中的 16 例表现出“连锁抑制”,而 8 例和 10 例 HLA-id 中的 1 例和 8 例中的 6 例没有表现出这种反应。最重要的是,当同时进行所有六项检测时,18 例 DBMC 中的 10 例、10 例 HLA-id 中的 5 例和 10 例 HLA-id 中的 0 例表现出长期特异性供者无反应性。我们提出,将这些检测结合起来进行聚类分析,将揭示能够安全进行 IS 最小化试验的耐受受者。这似乎在许多接受 DBMC 输注的受者中发生。